FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3190653321> ?p ?o ?g. }

• W3190653321 endingPage "103434" @default.
• W3190653321 startingPage "103434" @default.
• W3190653321 abstract "• Rechallenge ICI is an active and feasible strategy. • Rechallenge ICI could be considered on an individual basis. • Prospective studies are needed to clarify the role of rechallenge ICI. The role of immune checkpoint inhibitors (ICI) rechallenge in cancer patients is not defined. When ICIs are discontinued due to treatment completion or toxicity, another course of ICIs is feasible in clinical practice, but the amount of data is still quite limited to draw definitive conclusions. Here we report the results of a meta-analysis evaluating efficacy and safety of ICI rechallenge. PubMed, Embase, and Cochrane library were searched for studies reporting efficacy and safety of ICI rechallenge. Pooled analysis of response rate (ORR), median progression-free survival (mPFS) and median overall survival (mOS) were calculated. A total of 49 studies were included in qualitative and quantitative pooled analysis Overall response rate, mPFS and mOS were 21.8 % (range 0–70 %), 4.9 months (range 0–19.1 months) and 15.6 months (range 5.1–39 months), respectively. Incidence of any grade and grade 3−4 adverse events were 52.2 % (range 4–100 %) and 21.5 % (range 0–97.8 %), respectively. In the subgroup of patients who had previously discontinued ICI because of disease progression ORR, mPFS and mOS were 15.2 %, 2.9 and 7.9 months. Patients who had previously discontinued ICI because of toxicity achieved an ORR of 44 % and a mPFS of 13.2 months with the rechallenge. Our results suggest that rechallenge ICI is an active and feasible strategy, and it could be considered on an individual basis. However, this analysis is based on non-randomized studies. Prospective studies are needed to clarify the role of rechallenge after disease progression or adverse events." @default.
• W3190653321 created "2021-08-16" @default.
• W3190653321 creator A5004699983 @default.
• W3190653321 creator A5009884142 @default.
• W3190653321 creator A5022206145 @default.
• W3190653321 creator A5027018556 @default.
• W3190653321 creator A5037756908 @default.
• W3190653321 creator A5058439511 @default.
• W3190653321 creator A5073186349 @default.
• W3190653321 date "2021-09-01" @default.
• W3190653321 modified "2023-10-03" @default.
• W3190653321 title "Rechallenge of immune checkpoint inhibitors: A systematic review and meta-analysis" @default.
• W3190653321 cites W1809627231 @default.
• W3190653321 cites W1971554504 @default.
• W3190653321 cites W1990675339 @default.
• W3190653321 cites W1994993231 @default.
• W3190653321 cites W2059928795 @default.
• W3190653321 cites W2134119471 @default.
• W3190653321 cites W2135707184 @default.
• W3190653321 cites W2156261087 @default.
• W3190653321 cites W2267367070 @default.
• W3190653321 cites W2344626562 @default.
• W3190653321 cites W2366936450 @default.
• W3190653321 cites W2525217971 @default.
• W3190653321 cites W2560468940 @default.
• W3190653321 cites W2588686192 @default.
• W3190653321 cites W2589016133 @default.
• W3190653321 cites W2612002454 @default.
• W3190653321 cites W2760893760 @default.
• W3190653321 cites W2766153997 @default.
• W3190653321 cites W2766729634 @default.
• W3190653321 cites W2784235889 @default.
• W3190653321 cites W2790056391 @default.
• W3190653321 cites W2791483720 @default.
• W3190653321 cites W2799716227 @default.
• W3190653321 cites W2831487285 @default.
• W3190653321 cites W2886349478 @default.
• W3190653321 cites W2891486030 @default.
• W3190653321 cites W2895420406 @default.
• W3190653321 cites W2901191795 @default.
• W3190653321 cites W2926751463 @default.
• W3190653321 cites W2946436670 @default.
• W3190653321 cites W2948397884 @default.
• W3190653321 cites W2948598909 @default.
• W3190653321 cites W2955392295 @default.
• W3190653321 cites W2969687411 @default.
• W3190653321 cites W2969781963 @default.
• W3190653321 cites W2970026377 @default.
• W3190653321 cites W2973740076 @default.
• W3190653321 cites W2977365696 @default.
• W3190653321 cites W2977572233 @default.
• W3190653321 cites W2998298043 @default.
• W3190653321 cites W2998511916 @default.
• W3190653321 cites W3000398809 @default.
• W3190653321 cites W3005546631 @default.
• W3190653321 cites W3007099934 @default.
• W3190653321 cites W3015860015 @default.
• W3190653321 cites W3016806376 @default.
• W3190653321 cites W3017152148 @default.
• W3190653321 cites W3021204742 @default.
• W3190653321 cites W3024388727 @default.
• W3190653321 cites W3028423564 @default.
• W3190653321 cites W3029478055 @default.
• W3190653321 cites W3035324474 @default.
• W3190653321 cites W3035591035 @default.
• W3190653321 cites W3083702883 @default.
• W3190653321 cites W3085214897 @default.
• W3190653321 cites W3118977085 @default.
• W3190653321 cites W3134535644 @default.
• W3190653321 cites W3155768635 @default.
• W3190653321 doi "https://doi.org/10.1016/j.critrevonc.2021.103434" @default.
• W3190653321 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34343657" @default.
• W3190653321 hasPublicationYear "2021" @default.
• W3190653321 type Work @default.
• W3190653321 sameAs 3190653321 @default.
• W3190653321 citedByCount "22" @default.
• W3190653321 countsByYear W31906533212022 @default.
• W3190653321 countsByYear W31906533212023 @default.
• W3190653321 crossrefType "journal-article" @default.
• W3190653321 hasAuthorship W3190653321A5004699983 @default.
• W3190653321 hasAuthorship W3190653321A5009884142 @default.
• W3190653321 hasAuthorship W3190653321A5022206145 @default.
• W3190653321 hasAuthorship W3190653321A5027018556 @default.
• W3190653321 hasAuthorship W3190653321A5037756908 @default.
• W3190653321 hasAuthorship W3190653321A5058439511 @default.
• W3190653321 hasAuthorship W3190653321A5073186349 @default.
• W3190653321 hasConcept C120665830 @default.
• W3190653321 hasConcept C121332964 @default.
• W3190653321 hasConcept C126322002 @default.
• W3190653321 hasConcept C141071460 @default.
• W3190653321 hasConcept C143998085 @default.
• W3190653321 hasConcept C187960798 @default.
• W3190653321 hasConcept C197934379 @default.
• W3190653321 hasConcept C2776478404 @default.
• W3190653321 hasConcept C29730261 @default.
• W3190653321 hasConcept C61511704 @default.
• W3190653321 hasConcept C71924100 @default.
• W3190653321 hasConcept C95190672 @default.

• next